id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S15367 R63239 |
Bromley (Carbamazepine) (Epilepsy) (Controls exposed to LTG), 2023 | Major congenital anomaly | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
2.75 [0.44;17.33] C excluded (control group) |
2/27 3/106 | 5 | 27 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15368 R63252 |
Bromley (Carbamazepine) (Epilepsy) (Controls unexposed, sick), 2023 | Major congenital anomaly | during pregnancy (anytime or not specified) excluded | prospective cohort | unexposed, sick | Adjustment: No |
2.05 [0.32;13.00] C excluded (exposition period) |
2/27 3/80 | 5 | 27 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15199 R62341 |
Cohen (Carbamazepine) (Mixed indications) (Controls exposed to LTG), 2023 | Major congenital malformations (excluding genetic/chromosomal) | 1st trimester | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: Yes Partial overlapping |
0.91 [0.72;1.15] excluded (control group) |
90/2,674 314/8,339 | 404 | 2,674 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15198 R62334 |
Cohen (Carbamazepine) (Mixed indications) (Controls unexposed, NOS), 2023 | Major congenital malformations (excluding genetic/chromosomal) | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: No Partial overlapping | 1.11 [0.90;1.37] C | 90/2,674 147,928/4,866,362 | 148,018 | 2,674 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15852 R65260 |
Li (Carbamazepine) (Epilepsy) (Controls exposed to LTG), 2023 | Major congenital malformation | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
9.55 [0.47;192.46] C excluded (control group) |
3/31 0/38 | 3 | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15267 R62752 |
Li (Carbamazepine) (Epilepsy) (Controls unexposed, sick), 2023 | Major congenital malformation | during pregnancy (anytime or not specified) excluded | prospective cohort | unexposed, sick | Adjustment: No |
3.77 [0.92;15.39] C excluded (exposition period) |
3/31 7/253 | 10 | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12674 R47886 |
Mari (Carbamazepine), 2022 | Major foetal malformation | throughout pregnancy | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 1.15 [0.04;30.40] C | 1/29 0/11 | 1 | 29 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10225 R37454 |
The NAAED (Controls exposed to Lamotrigine, sick) (Indications NOS), 2022 | Major congenital malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.48 [0.93;2.35] C excluded (control group) |
31/1,122 44/2,333 | 75 | 1,122 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10226 R37460 |
The NAAED (Controls unexposed, disease free) (Indications NOS), 2022 | Major congenital malformations | 1st trimester | prospective cohort | unexposed, disease free | Adjustment: No | 2.82 [1.44;5.51] C | 31/1,122 12/1,201 | 43 | 1,122 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12683 R47919 |
Alsfouk (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2021 | Major congenital malformation | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.25 [0.21;7.34] C excluded (control group) |
5/31 2/15 | 7 | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12680 R47916 |
Alsfouk (Carbamazepine) (Controls unexposed, sick), 2021 | Major congenital malformation | during pregnancy (anytime or not specified) excluded | retrospective cohort | unexposed, sick | Adjustment: No |
5.58 [0.61;50.91] C excluded (exposition period) |
5/31 1/30 | 6 | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12903 R48938 |
Hosny (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2021 | Major birth defects | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.05 [0.00;3.56] C excluded (control group) |
1/31 0/1 | 1 | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12904 R48941 |
Hosny (Carbamazepine) (Controls unexposed, sick), 2021 | Major birth defects | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.67 [0.04;11.29] C | 1/31 1/21 | 2 | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12856 R48493 |
Thomas (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2021 | Major congenital malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
2.41 [0.32;18.26] C excluded (control group) |
23/490 1/50 | 24 | 490 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12857 R48501 |
Thomas (Carbamazepine) (Controls unexposed, disease free), 2021 | Major congenital malformations | 1st trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No |
1.57 [0.77;3.20] excluded (control group) |
21/389 11/319 | 32 | 389 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12858 R48505 |
Thomas (Carbamazepine) (Controls unexposed, sick), 2021 | Major congenital malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: Yes | 0.99 [0.50;1.80] | 23/490 16/340 | 39 | 490 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9595 R33978 |
AlSheikh (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2020 | Fetal/neonatal malformation | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
16.71 [0.56;499.27] C excluded (control group) |
1/5 0/20 | 1 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9596 R33981 |
AlSheikh (Carbamazepine) (Controls unexposed, sick), 2020 | Fetal/neonatal malformation | during pregnancy (anytime or not specified) excluded | prospective cohort | unexposed, sick | Adjustment: No |
1.75 [0.08;36.29] C excluded (exposition period) |
1/5 1/8 | 2 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9632 R34252 |
Meador (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2020 | Major congenital malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.62 [0.17;14.92] C excluded (control group) |
1/14 5/110 | 6 | 14 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9633 R34256 |
Meador (Carbamazepine) (Controls unexposed, disease free), 2020 | Major congenital malformations | 1st trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No |
4.00 [0.34;47.23] C excluded (control group) |
1/14 2/106 | 3 | 14 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9634 R34260 |
Meador (Carbamazepine) (Controls unexposed, sick), 2020 | Major congenital malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 1.08 [0.06;19.05] C | 1/14 1/15 | 2 | 14 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9723 R34624 |
Huber-Mollema (Carbamazepine), 2019 | Congenital malformations | throughout pregnancy | prospective cohort | exposed to other treatment, sick | Adjustment: No | 2.55 [0.60;10.78] C | 4/37 4/88 | 8 | 37 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9679 R34459 |
Vajda (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2019 | Fetal malformations | at least 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.20 [0.65;2.21] C excluded (control group) |
24/409 20/406 | 44 | 409 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9680 R34460 |
Vajda (Carbamazepine) (Controls unexposed, sick), 2019 | Fetal malformations | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 2.07 [0.80;5.33] | 24/409 5/176 | 29 | 409 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9678 R34449 |
Tomson (Carbamazepine), 2018 | Major congenital malformation | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.91 [1.41;2.58] C | 107/1,957 74/2,514 | 181 | 1,957 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9760 R34847 |
Bank (Carbamazepine) (Mixed indications), 2017 | Major Malformation | during pregnancy (anytime or not specified) excluded | prospective cohort | exposed to other treatment, sick | Adjustment: No |
16.38 [0.60;447.84] C excluded (exposition period) |
1/8 0/36 | 1 | 8 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9597 R33984 |
Arkilo (Carbamazepine), 2015 | Major malformations | during pregnancy (anytime or not specified) excluded | retrospective cohort | exposed to other treatment, sick | Adjustment: No |
1.39 [0.03;73.79] C excluded (exposition period) |
0/16 0/22 | 0 | 16 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9763 R34863 |
Ban (Carbamazepine) (Mixed indications) (Controls exposed to Lamotrigine, sick), 2015 | Any major anomaly | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.86 [0.38;1.91] C excluded (control group) |
13/343 12/273 | 25 | 343 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9764 R34869 |
Ban (Carbamazepine) (Mixed indications) (Controls unexposed NOS), 2015 | Any major anomaly | 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: Yes | 1.42 [0.68;2.93] | 13/343 6,922/257,153 | 6,935 | 343 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9605 R34053 |
Barroso (Carbamazepine), 2015 | Major anomalies | during pregnancy (anytime or not specified) excluded | retrospective cohort | unexposed, disease free | Adjustment: No |
1.35 [0.17;10.95] C excluded (exposition period) |
1/12 20/316 | 21 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9681 R34461 |
Vanya (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2015 | Major congenital malformations | throughout pregnancy | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.94 [0.07;56.76] C excluded (control group) |
1/10 0/6 | 1 | 10 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9682 R34463 |
Vanya (Carbamazepine) (Controls unexposed, sick), 2015 | Major congenital malformations | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 6.88 [0.25;186.69] C | 1/10 0/20 | 1 | 10 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9655 R34376 |
Campbell (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014 | Major malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.10 [0.70;1.70] excluded (control group) |
43/1,657 49/2,098 | 92 | 1,657 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9656 R34378 |
Campbell (Carbamazepine) (Controls unexposed, sick), 2014 | Major malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 1.08 [0.58;2.03] C | 43/1,657 13/541 | 56 | 1,657 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9643 R34317 |
Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 | Major congenital malformation | throughout pregnancy | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No Partial overlapping |
0.86 [0.48;1.55] C excluded (control group) |
20/685 28/833 | 48 | 685 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9645 R34325 |
Veiby (Carbamazepine) (Controls unexposed, disease free) (Mixed indications), 2014 | Major malformations | throughout pregnancy | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes Partial overlapping |
1.06 [0.68;1.66] excluded (control group) |
20/685 22,371/771,412 | 22,391 | 685 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9646 R34328 |
Veiby (Carbamazepine) (Controls unexposed, sick) (Mixed indications), 2014 | Major malformations | throughout pregnancy | population based cohort retrospective | unexposed, sick | Adjustment: No Controls: epilepsy indication Partial overlapping | 1.04 [0.64;1.69] C | 20/685 106/3,773 | 126 | 685 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9658 R34388 |
Cassina (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2013 | Major congenital anomalies | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
6.94 [0.39;122.72] C excluded (control group) |
8/120 0/46 | 8 | 120 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9659 R34390 |
Cassina (Carbamazepine) (Controls unexposed, disease free) (Mixed indications), 2013 | Major congenital anomalies | 1st trimester | prospective cohort | unexposed, disease free | Adjustment: No | 2.22 [0.98;5.05] C | 8/120 25/803 | 33 | 120 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9625 R34223 |
Källén (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2013 | Relatively severe malformations | early pregnancy | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No Partial overlapping |
1.13 [0.74;1.72] C excluded (control group) |
58/1,511 37/1,084 | 95 | 1,511 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9626 R34231 |
Källén (Carbamazepine) (Controls unexposed, NOS) (Indications NOS), 2013 | Relatively severe malformations | early pregnancy | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Partial overlapping | 1.04 [0.80;1.35] | 58/1,511 49,499/1,575,847 | 49,557 | 1,511 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9653 R34363 |
Bànhidy (Carbamazepine), 2011 | Total congenital abnormalities | throughout pregnancy | case control | unexposed, sick | Adjustment: No Matched | 0.67 [0.19;2.33] C | 8/18 12/22 | 20 | 18 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9608 R34065 |
Charlton (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2011 | Major congenital malformations | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
1.38 [0.39;4.95] C excluded (control group) |
13/311 3/98 | 16 | 311 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9609 R34068 |
Charlton (Carbamazepine) (Controls unexposed, sick), 2011 | Major congenital malformations | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: No | 1.71 [0.87;3.36] | 13/311 22/902 | 35 | 311 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9628 R34240 |
Mawer (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2010 | Major malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.55 [0.07;4.05] C excluded (control group) |
2/66 2/37 | 4 | 66 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9629 R34242 |
Mawer (Carbamazepine) (Controls unexposed, disease free), 2010 | Major malformations | 1st trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
1.45 [0.23;7.37] excluded (control group) |
2/66 6/285 | 8 | 66 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9630 R34244 |
Mawer (Carbamazepine) (Controls unexposed, sick), 2010 | Major malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 1.25 [0.11;14.24] C | 2/66 1/41 | 3 | 66 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9669 R34417 |
Kini (Carbamazepine) (Controls unexposed, sick), 2006 | Major malformations | during pregnancy (anytime or not specified) excluded | retrospective cohort | unexposed, sick | Adjustment: No |
1.36 [0.36;5.23] excluded (exposition period) |
5/94 4/101 | 9 | 94 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9631 R34246 |
Meador (Carbamazepine), 2006 | Congenital malformations | during pregnancy (anytime or not specified) excluded | prospective cohort | exposed to other treatment, sick | Adjustment: No |
4.62 [0.53;40.24] C excluded (exposition period) |
5/110 1/98 | 6 | 110 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9648 R34331 |
Viinikainen (Carbamazepine) (Controls unexposed, sick) a, 2006 | Major malformations | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 5.26 [0.27;104.15] C | 3/72 0/52 | 3 | 72 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9604 R34049 |
Barqawi (Carbamazepine), 2005 | Major congenital anomalies | during pregnancy (anytime or not specified) excluded | retrospective cohort | unexposed, sick | Adjustment: No |
1.13 [0.02;60.37] C excluded (exposition period) |
0/16 0/18 | 0 | 16 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9665 R34412 |
Kaaja (Carbamazepine), 2003 | Major malformation | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 3.36 [0.73;15.46] C | 10/363 2/239 | 12 | 363 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9614 R34143 |
Dean (Carbamazepine), 2002 | Major congenital malformations | at least 1st trimester | retrospective cohort | unexposed, sick | Adjustment: No | 2.32 [0.47;11.54] C | 8/70 2/38 | 10 | 70 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9662 R34402 |
Diav-Citrin (Carbamazepine), 2001 | Major congenital anomalies (among live born and elective termination of pregnancy) | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No Matched | 1.98 [0.62;6.30] C | 6/100 6/192 | 12 | 100 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9621 R34201 |
Holmes (Carbamazepine) (Controls unexposed, disease free), 2001 | Major malformations | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, disease free excluded | Adjustment: Yes |
3.00 [0.60;16.00] excluded (control group) |
3/58 9/508 | 12 | 58 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9622 R34210 |
Holmes (Carbamazepine) (Controls unexposed, sick), 2001 | Major malformations | during pregnancy (anytime or not specified) excluded | retrospective cohort | unexposed, sick | Adjustment: No |
12.52 [0.63;246.98] C excluded (exposition period) |
3/58 0/98 | 3 | 58 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9623 R34219 |
Hvas (Carbamazepine) (Controls unexposed, disease free), 2000 | Major congenital malformations | 1st trimester | retrospective cohort | unexposed, disease free excluded | Adjustment: No |
4.81 [1.15;20.08] C excluded (control group) |
2/37 280/23,827 | 282 | 37 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9624 R34221 |
Hvas (Carbamazepine) (Controls unexposed, sick), 2000 | Major congenital malformations | 1st trimester | retrospective cohort | unexposed, sick | Adjustment: No | 15.29 [0.72;326.31] C | 2/37 0/106 | 2 | 37 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9657 R34386 |
Canger (Carbamazepine), 1999 | Severe malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 3.48 [0.19;63.08] C | 7/113 0/25 | 7 | 113 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9671 R34434 |
Samrén (Carbamazepine), 1999 | Major congential abnormalities | at least 1st trimester | retrospective cohort | unexposed, disease free | Adjustment: No Matched | 2.60 [1.40;5.00] | 14/376 29/2,000 | 43 | 376 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9768 R34928 |
Nulman (Carbamazepine) (Controls unexposed, NOS) (Mixed indications), 1997 | Malformations (major) | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No Matched | 1.03 [0.14;7.75] C | 2/35 2/36 | 4 | 35 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9672 R34436 |
Steegers-Theunissen (Carbamazepine), 1994 | Major malformations (ICD9 British Paediatric Association System) | during pregnancy (anytime or not specified) excluded | prospective cohort | unexposed, disease free | Adjustment: No |
2.81 [0.38;20.68] C excluded (exposition period) |
2/39 2/106 | 4 | 39 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9670 R34431 |
Robert (Carbamazepine), 1986 | Major malformations | 1st trimester | retrospective cohort | unexposed, sick | Adjustment: No | 13.80 [0.22;853.65] C | 0/3 0/35 | 0 | 3 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 27 studies | 1.48 [1.23;1.77] | 205,182 | 12,653 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine) (Mixed indications) (Controls unexposed, NOS; 2: Carbamazepine; 3: Controls unexposed, disease free) (Indications NOS; 4: Carbamazepine) (Controls unexposed, sick; 5: Carbamazepine) (Controls unexposed, sick; 6: Carbamazepine) (Controls unexposed, sick; 7: Carbamazepine; 8: Carbamazepine) (Controls unexposed, sick; 9: Carbamazepine; 10: Carbamazepine) (Mixed indications) (Controls unexposed NOS; 11: Carbamazepine) (Controls unexposed, sick; 12: Carbamazepine) (Controls unexposed, sick; 13: Carbamazepine) (Controls unexposed, sick) (Mixed indications; 14: Carbamazepine) (Controls unexposed, disease free) (Mixed indications; 15: Carbamazepine) (Controls unexposed, NOS) (Indications NOS; 16: Carbamazepine; 17: Carbamazepine) (Controls unexposed, sick; 18: Carbamazepine) (Controls unexposed, sick; 19: Carbamazepine) (Controls unexposed, sick) ; 20: Carbamazepine; 21: Carbamazepine; 22: Carbamazepine; 23: Carbamazepine) (Controls unexposed, sick; 24: Carbamazepine; 25: Carbamazepine; 26: Carbamazepine) (Controls unexposed, NOS) (Mixed indications; 27: Carbamazepine;
Asymetry test p-value = 0.0000 (by Egger's regression)
slope=0.1210 (0.0945); intercept=0.7606 (0.3039); t=2.5029; p=0.0000
excluded 9623, 9621, 9628, 9629, 9608, 9658, 9625, 9655, 9643, 9645, 9763, 9681, 9679, 9595, 9632, 9633, 12683, 12903, 12856, 12857, 10225, 15367, 15199, 15852